Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Pipenzolate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 10/20 | 0.98 |
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.98 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | HRH1 | P35367 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pipenzolate SCHEMBL31682328 | 0.99 | CHRM2 (1.00) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Pipenzolate SCHEMBL25957021 | 0.99 | CHRM2 (1.00) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Bromide SCHEMBL21530608 | 0.88 | RAB9A (0.79) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Mepenzolate SCHEMBL17008166 | 0.88 | CHRM3 (1.00) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Mepenzolate SCHEMBL99030 | 0.88 | CHRM3 (1.00) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Mepenzolate SCHEMBL15575981 | 0.88 | CHRM3 (1.00) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Mepenzolate SCHEMBL147471 | 0.88 | CHRM3 (1.00) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Mepenzolate SCHEMBL15575855 | 0.88 | CHRM3 (1.00) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Mepenzolate SCHEMBL19411950 | 0.86 | CHRM3 (0.97) | RAB9ACHRM2CHRM3KCNH2CHRM1 | |
| Mepenzolate SCHEMBL15865414 | 0.86 | CHRM3 (0.97) | RAB9ACHRM2CHRM3KCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-08-10 | — | — | US | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2017147104-A1 | MUSCARINIC M2-ANTAGONIST COMBINATIONS | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-08-31 | — | — | WO | claimed |
| US-20160257952-A1 | IDENTIFICATION OF STRUCTURALLY SIMILAR SMALL MOLECULES THAT ENHANCE THERAPEUTIC EXON SKIPPING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-08 | — | — | US | claimed |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER LTD. (CH) | 2014-06-19 | — | — | US | claimed |
| EP-2691367-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | Hovione Inter Ltd. (CH) | 2014-02-05 | — | — | EP | claimed |
| CN-103502211-A | Electrophilic alkylating reagents, preparation and use thereof | HOVIONE FARMACIENCIA S A | 2014-01-08 | — | — | CN | claimed |
| EP-2665739-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2012131286-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER. LTD (CH) | 2012-10-04 | — | — | WO | claimed |
| WO-2012100248-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2012-07-26 | — | — | WO | claimed |
| EP-2188630-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009045443-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2009-04-09 | — | — | WO | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5316772-A | Bilayered oral pharmaceutical composition with pH dependent release | SOLVAY & CIE, S.A. (SOCIETE ANONYME) (BE) | 1994-05-31 | — | — | US | claimed |
| WO-1992011001-A1 | ORAL PHARMACEUTICAL COMPOSITION | SOLVAY (SOCIETE ANONYME) (BE) | 1992-07-09 | — | — | WO | claimed |
| US-5008111-A | Pretreating skin with anticholinergic quaternary ammonium salt to suppress perspiration | SCHERING CORPORATION (US) | 1991-04-16 | — | — | US | claimed |
| US-4824676-A | ANTICHOLINERGIC AGENT TO SUPPRESS PERSPIRATION | SCHERING CORPORATION (US) | 1989-04-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | SARS1, EIF2AK2, ACE2 | CHRM2 4822/4885CHRM3 4594/4885CHRM1 4876/4885 |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | MGMT, MCL1, TOP2B | CHRM2 2607/4885CHRM3 3125/4885CHRM1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.